Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib and Sirolimus for HIV-1 Control After ART Interruption
NCT07081763Phase 2Not yet recruiting
- Sponsor
- ANRS
- Start
- May 2027
- Primary completion
- May 2029
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
01
Overview
A Phase 2 trial of baricitinib, sirolimus in human immunodeficiency virus infection (HIV), sponsored by ANRS. Planned start May 2027; status: not yet recruiting.
02
Drugs
baricitinibsirolimus
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07081763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07081763.